October 7, 2025 — Leads & Copy — Propanc Biopharma, Inc. (Nasdaq: PPCB) announced its fiscal year-end update following the filing of its annual 10-K report with the Securities and Exchange Commission on September 29, 2025. The reporting period concluded on June 30, 2025.
Significant changes to its financial position allowed the Company to complete an initial public offering and uplist to Nasdaq on August 14, 2025. These developments are expected to support future operational and research activities. Propanc’s CEO, James Nathanielsz, stated, “The Company is focused on advancing our lead therapeutic candidate and further building our intellectual property portfolio with various development milestones anticipated by the end of 2025 and throughout 2026. We are also actively engaged in collaborative efforts with regards to our clinical pipeline.” Mr. Nathanielsz added, “In addition, we intend to create a $100 Million or greater, digital asset treasury over the next twelve months.”
Key financial data from the Company’s filing on June 30, 2025, includes:
Total assets increased from over $72,000 to $19.6 Million. The growth in assets is primarily attributed to prepaid service contracts related to market awareness, advisory, accounting, finance, manufacturing, and R&D activities. Stockholders’ equity rose to $13.9 Million from a deficit of $3.8 Million. Following the NASDAQ uplisting, Propanc entered into an underwriting agreement with D Boral Capital and completed an offering of 1,000,000 common shares generating gross proceeds of $4 Million.
Propanc Biopharma, Inc. is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
Source: Propanc Biopharma, Inc.
